OVID THERAPEUTICS INC (OVID) Stock Price, Quote, News and Overview
NASDAQ:OVID - Nasdaq - US6904691010 - Common Stock - Currency: USD
OVID Quote, Performance and Key Statistics
0.6175
+0.05 (+8.91%)
The current stock price of OVID is 0.6175 USD. In the past month the price decreased by -13%. In the past year, price decreased by -83.31%.
OVID Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About OVID
Company Profile
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2017-05-05. The firm is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. The company is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. The company develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. The company also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Company Info
OVID THERAPEUTICS INC
441 Ninth Avenue, 14Th Floor
New York City NEW YORK 10036 US
CEO: Jeremy M. Levin
Employees: 40
Company Website: https://ovidrx.com/
Investor Relations: http://investors.ovidrx.com
Phone: 12127764381
OVID THERAPEUTICS INC / OVID FAQ
What is the stock price of OVID THERAPEUTICS INC today?
The current stock price of OVID is 0.6175 USD. The price increased by 8.91% in the last trading session.
What is the ticker symbol for OVID THERAPEUTICS INC stock?
The exchange symbol of OVID THERAPEUTICS INC is OVID and it is listed on the Nasdaq exchange.
On which exchange is OVID stock listed?
OVID stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OVID THERAPEUTICS INC stock?
14 analysts have analysed OVID and the average price target is 3.45 USD. This implies a price increase of 458.86% is expected in the next year compared to the current price of 0.6175. Check the OVID THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OVID THERAPEUTICS INC worth?
OVID THERAPEUTICS INC (OVID) has a market capitalization of 43.85M USD. This makes OVID a Nano Cap stock.
How many employees does OVID THERAPEUTICS INC have?
OVID THERAPEUTICS INC (OVID) currently has 40 employees.
What are the support and resistance levels for OVID THERAPEUTICS INC (OVID) stock?
OVID THERAPEUTICS INC (OVID) has a resistance level at 0.65. Check the full technical report for a detailed analysis of OVID support and resistance levels.
Is OVID THERAPEUTICS INC (OVID) expected to grow?
The Revenue of OVID THERAPEUTICS INC (OVID) is expected to grow by 98.35% in the next year. Check the estimates tab for more information on the OVID EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OVID THERAPEUTICS INC (OVID) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OVID, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OVID, evaluating the profitability, health, valuation and growth aspects
- OVID THERAPEUTICS INC (OVID) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OVID THERAPEUTICS INC (OVID) Sales and EPS estimates to see what analysts future expectations are.
- OVID THERAPEUTICS INC (OVID) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OVID THERAPEUTICS INC (OVID) Insider and Institutional Ownership to learn about the owners and their transactions.
- OVID THERAPEUTICS INC (OVID) Stock Chart to make your own analysis
- OVID THERAPEUTICS INC (OVID) Latest news and press-releases to stay up to date.
Does OVID THERAPEUTICS INC (OVID) stock pay dividends?
OVID does not pay a dividend.
When does OVID THERAPEUTICS INC (OVID) report earnings?
OVID THERAPEUTICS INC (OVID) will report earnings on 2025-03-17, after the market close.
What is the Price/Earnings (PE) ratio of OVID THERAPEUTICS INC (OVID)?
OVID THERAPEUTICS INC (OVID) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
What is the Short Interest ratio of OVID THERAPEUTICS INC (OVID) stock?
The outstanding short interest for OVID THERAPEUTICS INC (OVID) is 1.48% of its float. Check the ownership tab for more information on the OVID short interest.
OVID Technical Analysis
OVID Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OVID. While OVID seems to be doing ok healthwise, there are quite some concerns on its profitability.
OVID Financial Highlights
Over the last trailing twelve months OVID reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS increased by 31.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.66% | ||
| ROE | -42.6% | ||
| Debt/Equity | 0 |
OVID Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to OVID. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 44.8% and a revenue growth 98.35% for OVID